Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy ProfilingSabrina Weber, Ellen Heitzer, Benjamin Spiegl et al.|Cancers|2020Cited by 69
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancerTina Moser, Michael R. Speicher, Julie Waldispuehl‐Geigl et al.|npj Precision Oncology|2020Cited by 26
Supplementary Figure from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor ResponseQing Zhou, Ellen Heitzer, Simon Peter Gampenrieder et al.|Unknown|2023Cited by 0
Supplementary Figure from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor ResponseQing Zhou, Ellen Heitzer, Simon Peter Gampenrieder et al.|Unknown|2023Cited by 0
Supplementary Figure from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor ResponseQing Zhou, Ellen Heitzer, Simon Peter Gampenrieder et al.|Unknown|2023Cited by 0